

### This week in therapeutics

Indication	Target/marker/pathway	Summary	Licensing status	Publication and contact information
<b>Cancer</b>				
Solid tumors	TNF-like weak inducer of apoptosis receptor (TNFRSF12A; TWEAKR; FN14)	<p>Mouse and cell culture studies identified an antibody-drug conjugate against FN14 that could help treat FN14<sup>+</sup> solid tumors. In a panel of five FN14<sup>+</sup> human breast cancer cell lines, a humanized, dimeric, single-chain anti-FN14 antibody fused to recombinant gelonin toxin was cytotoxic and had IC<sub>50</sub> values of 0.1–2.4 nM. In a mouse xenograft model for FN14<sup>+</sup> human breast cancer, the FN14-targeted immunotoxin significantly decreased tumor growth (<math>p &lt; 0.01</math>) and increased survival (<math>p &lt; 0.0001</math>) compared with saline. Next steps could include testing the targeted immunotoxin in other FN14<sup>+</sup> solid tumors.</p> <p><b>SciBX 6(27); doi:10.1038/scibx.2013.682</b> Published online July 18, 2013</p>	Patent and licensing status unavailable	<p>Zhou, H. <i>et al. Cancer Res.</i>; published online May 30, 2013; doi:10.1158/0008-5472.CAN-13-0187 <b>Contact:</b> Michael G. Rosenblum, The University of Texas MD Anderson Cancer Center, Houston, Texas e-mail: <a href="mailto:mrosenbl@mdanderson.org">mrosenbl@mdanderson.org</a></p>